The Rise and Fall of “Ozempic Vulva”

A term with a lifespan

Most health scares are hard to measure. This one is not, because you can watch it happen in the search data.

In one month, "Ozempic vulva" was searched roughly 54,900 times in the United States. The next month, about 30,900. The month after, 22,000. Then it fell away to a few hundred a month, where it has stayed. That is our analysis of third-party keyword data, and the shape of it is unmistakable: a spike, a decay, and a long quiet tail.

Between the spike and the tail, a very large number of women typed those two words into a search bar and were frightened by what came back.

This is a piece about what the phrase was built on, and what it cost.

What the labels say, which is nothing

Start where a reporter should start, with the primary document.

The current prescribing information for Wegovy contains no occurrence of the words vaginal, vulvovaginal, candidiasis or genital mycotic infection. Not one¹. The Zepbound label contains none of those terms either².

These are not thin documents. They enumerate belching. They enumerate hair loss and flatulence and dry throat, at rates of one and two percent. If a vulvar effect were an observed, drug-attributable finding of any frequency, this is precisely where it would appear.

So the phrase never described a documented effect of the medication. It described a set of experiences women were having during rapid weight loss, given a brand name.

Where the name came from

"Ozempic vulva" arrived in the wake of "Ozempic face" — a coinage that worked because it was true enough, memorable, and slightly cruel. The formula was reusable, and it got reused: Ozempic butt, Ozempic teeth, Ozempic feet. Each is a real-ish observation about what losing weight quickly does to a body, wrapped in a drug's brand name that implies causation the evidence does not carry.

It is a good formula for traffic. Our analysis of what ranks for the term shows the front page held by a plastic surgery association, a large consumer health publisher, and a telehealth company that sells GLP-1 prescriptions — alongside, at the very top, a single physician's practice website. The incentives are not hidden.

What women actually experienced

Here is where this piece has to be careful, because dismissing the phrase would be as wrong as amplifying it.

Women reported dryness, changed sensation, and a sense that tissue looked or felt different. Those reports are consistent and there is no reason to doubt them.

There are also perfectly ordinary explanations available. Losing a great deal of weight quickly changes tissue everywhere; the face changed visibly, and there was never a reason to think the vulva was exempt. Low oestrogen produces exactly this constellation — the condition clinicians call genitourinary syndrome of menopause, which has an international consensus behind its definition³, and which for a woman in her forties may simply have arrived in the same year as her prescription. Sexual function after major weight loss has been studied properly in bariatric patients⁴, and the honest summary is that it changes without changing in one direction.

And the thing nobody put in a headline: there is no research on the vulvovaginal effects of these drugs in women. No trial, no cohort. Every mechanism above is borrowed from another setting.

The cost of a name

A phrase like this does three things at once.

It gives women language for something they were experiencing and had no word for, which is genuinely valuable and is why it spread.

It attributes that experience to a specific cause, on no evidence, which sends people to the wrong conversation — worrying about a medication rather than asking about oestrogen, or an infection, or the SGLT2 inhibitor also in the cabinet.

And it makes the subject embarrassing, because a body part plus a drug name is a joke format. Women who might have raised dryness with a clinician now had to raise "Ozempic vulva" instead. Several told us they did not.

The searches have collapsed. The symptoms have not. That gap is the actual story, and it is the reason we are writing about a term six months after it stopped trending.

What is worth doing

Dryness and irritation are treatable, and treatable regardless of what caused them — moisturisers, lubricants, and where appropriate local oestrogen are established options. Itching, unusual discharge or odour points toward infection, which is tested rather than assumed. And anything arriving alongside hot flushes or cycle changes is a perimenopause conversation wearing someone else's name.

None of that requires knowing whether the drug did it.

More in this territory: the body you are now in, "Ozempic face" explained, and what a GLP-1 does to a marriage.